About AREVA Med

Based on an R&D program started in 2005 by our founder, Patrick Bourdet, AREVA Med has developed new processes for producing high-purity lead-212 (212Pb), a rare radioactive isotope. 212Pb is currently at the heart of promising research projects in nuclear medicine to develop new treatments against cancer.

The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells.

AREVA Med was officially created in 2009 and is an affiliate of the AREVA Group.

  • Achievements

    Since its creation in 2009, AREVA Med has reached several important milestones, contributing to significant breakthroughs in nuclear medicine.

    • First clinical trial with lead-212 (212Pb) launched in 2012; patient enrollment complete in 2014
    • First manufacturing facility to produce high-purity 212Pb operational since 2013
    • Strategic acquisition of Macrocyclics, world leader in chelating agent production
    • Strategic collaborations in cancer research:
      • Roche
      • National Cancer Institute (NCI)
      • University of Alabama at Birmingham (UAB) Cancer Center
      • University of Cincinnati (UC)
      • French National Institute of Health and Medical Research (Inserm)
      • University of California, San Diego (UCSD) Moores Cancer Center
      • RadioMedix
      • Morphotek
      • Nordic Nanovector

    Recognition and awards:

    • Clinton Global Initiative (CGI)
    • Marie Curie Medal from the French Society of Nuclear Energy (SFEN)
  • Strategy

    Laboratoire Maurice Tubiana (LMT)


    Confronted with the scarcity of radioisotopes suitable for targeted alpha therapy, AREVA Med has developed a process for extracting and purifying 212Pb from an abundant supply of thorium derived from AREVA’s former mining activities.

    Thanks to several patented innovations implemented in the cutting-edge Laboratoire Maurice Tubiana, AREVA Med can produce high-purity 212Pb to conduct preclinical studies and clinical trials, and to develop new cancer treatments.

    Before new drugs become available to doctors and patients, researchers must demonstrate the drug’s therapeutic safety and efficacy. AREVA Med and its scientific research partners are making great strides toward this end through extensive research.

    In 2012, AREVA Med launched the first Phase 1 clinical trial with 212Pb. Since then, the focus is on moving other preclinical candidates into clinical development by continuing studies that target different pathologies using various vectors.

    Thanks to patented innovations and increased 212Pb production capacity achieved in the U.S. and in France, AREVA Med now seeks to expand its partnership portfolio with academics and biotechs. 

    Interested in partnering with AREVA Med?

    Please contact Nicolas.Bozovic@areva.com


  • Scientific Team

    AREVA Med's Scientific Team

    Julien Torgue, Ph.D., AREVA Med Scientific Director since 2010

    AREVA Med’s Scientific team is composed of qualified personnel with many years of cumulative expertise in the Targeted Alpha Therapy (TAT) field. This team has already proven its ability to bring new therapies to the clinic, and is now equipped with a preclinical lab dedicated to TAT with 212Pb.

    “Over the years, AREVA Med has assembled a team of experienced scientists (chemists, biologists, experimentation) to support its internal and collaborative research programs.  Our in-house capabilities have allowed us to significantly speed up our research and collection of the necessary data to support additional Investigational New Drug (IND) applications.”

    AREVA Med's Scientific Advisory Committee

    Darrell Fisher, PhD

    Dr. Fisher is a medical physicist at Versant Medical Physics and Radiation Safety. Previously, at Pacific Northwest National Laboratory, he led the Laboratory’s Isotope Sciences Program, where he was responsible for radioisotope production and applications research. This work included production and testing of radium-224 generator systems.

    Fisher specializes in the health effects and dosimetry of exposure to radiation, radioactive materials, and medically administered radiopharmaceuticals. He received his doctorate in nuclear engineering sciences from the University of Florida in 1978, and has been a Laboratory research scientist since that time.

    On loan to the new U.S. Department of Homeland Security, he also served as science advisor at U.S. Customs and Border Protection Headquarters in Washington, DC (2003 – 2005). He is an adjunct faculty member at the University of Washington and Washington State University, and he is active in the Health Physics Society, American Nuclear Society, and Society of Nuclear Medicine and Molecular Imaging (SNMMI).

    Ruby Meredith, MD, PhD

    Dr. Meredith is a Professor of Radiation Oncology at the University of Alabama at Birmingham and a Senior Scientist at the UAB Comprehensive Cancer Center.  Among her honors are an Endowed Chair established in her name, Best Doctors Listings for more than ten years, and induction as a Fellow in the American College of Radiation Oncology and the American Society for Therapeutic Radiology and Oncology.  She served on the Advisory Panel for the National Biotracer Facility Project, as well as multiple other radionuclide related councils.  These include over fifteen years on the Medical Internal Radiation Dosimetry committee of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).  Her basic science background has facilitated the development and realization of multiple clinical trials.  She has been involved in 50 clinical trials for targeted radionuclide therapy and has served as a Principal Investigator for AREVA Med’s Phase 1 clinical trial of Intraperitoneal 212Pb-TCMC-trastuzumab for HER-2 expressing malignancy.

    For more details:  http://www.uab.edu/medicine/radonc/en/faculty2/ruby-f-meredith-md-phd

    Olivier Rixe, MD, PhD

    Dr. Rixe is an internationally recognized expert in the field of developmental therapeutics in Oncology. Dr. Rixe received his MD from the Pierre and Marie Curie University of Paris in 1993, and completed 4 years of training in medical oncology and internal medicine in Paris. He joined in 1992 the laboratory of Tito Fojo at the NCI's Medical Oncology Branch.

    Following his training at the NCI, Dr. Rixe received his PhD from the University Paris 7 in Paris, France. He served as a senior medical oncologist at Pitie-Salpetriere Hospital in Paris, then in the Phase 1 Unit at Gustave Roussy Institute in Villejuif, France. Dr Rixe  was appointed Professor of Medical Oncology in 2003 at Pierre and Marie Curie University (Paris 6). In 2008, Dr. Rixe joined the Medicine Branch at the National Cancer Institute in Bethesda, MD as a staff clinician.

    In 2009, Dr. Rixe joined the University of Cincinnati as a Professor of Medicine and assumed the position of director of the Experimental Therapeutics Program.  Dr. Rixe has published more than 120 peer-reviewed papers.

    In 2012, Dr. Rixe joined Georgia Health Sciences University in Atlanta, GA, as professor of medicine and director of the experimental therapeutics program in the hematology / oncology division.

    In 2014, Dr. Rixe joined the University of New Mexico Cancer Center in Albuquerque, NM, as associate director for clinical research. 

    Brenda Sandmaier, MD

    Dr. Sandmaier is a Member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, and Professor of Medicine in the Division of Oncology at the University of Washington, both in Seattle, Washington. Dr. Sandmaier has carried out research with radiolabeled monoclonal antibodies in preclinical studies since 1986.  Her most recent focus is using alpha emitters.

    Dr. Sandmaier also has research expertise in the translation of preclinical findings to clinical trials in the area of allogeneic hematopoietic cell transplantation for hematologic malignancies. She has developed and is Principle Investigator of 20 such clinical trials, including a randomized Phase III study, open at multiple institutions (national and international).

    Dr. Sandmaier has successfully submitted and held four investigator sponsored INDs.

    George Sgouros, PhD

    Dr. Sgouros is Professor of Radiology and Radiation Oncology, Director of Radiopharmaceutical Dosimetry Section of the Division of Nuclear Medicine, Johns Hopkins University, School of Medicine. He has been principal investigator or program leader on numerous grants with over twenty years experience in modeling and dosimetry of internally administered radionuclides with a particular emphasis on patient-specific dosimetry, alpha-particle dosimetry and mathematical modeling of radionuclide therapy. 

    Dr. Sgouros’s lab is currently engaged in pre-clinical research investigating targeted alpha-emitter therapy of metastatic cancer.  He is author on more than 100 peer-reviewed articles, as well as several book chapters and review articles. 

    He is chairman of the Medical Internal Radionuclide Dose (MIRD) Committee as well as steering committee member, of the American Association of Physicists in Medicine (AAPM), Task Group on Internal Emitter Dosimetry and member of the National Council on Radiation Protection and Measurements (NCRP) Committee on Uncertainties in Internal Radiation Dosimetry. 

    He has served as chairman of the Dosimetry & Radiobiology Panel at a Department of Energy Workshop on alpha-emitters in medical therapy and, in the early 90’s, provided the physics/dosimetry support for the first FDA-approved human trial of targeted alpha-emitter therapy.  He has also served on several NIH study sections and on the Oncological Sciences IRG Study Section Boundaries Team.

  • Research Partners


    In 2012, Roche and AREVA Med launched a strategic alliance; the objective is to create a novel, advanced alpha radioimmunotherapy platform to target and kill cancer cells. The agreement is focused on malignant disease with a high unmet medical need.  As part of this new alliance, Roche and AREVA Med have built a research laboratory located in France. Operational since 2013, ARCoLab (AREVA Med Roche Common Laboratory) is dedicated to the co-development of targeted alpha therapy (TAT), an innovative and promising approach in the fight against cancer.  A joint team of researchers from both Roche and AREVA Med currently evaluate the anti-tumor efficiency of TAT in different preclinical models.


    Since 2015, new partnerships have been signed with innovative biotechs around the world


    In 2015, AREVA Med and RadioMedix, a clinical phase biotechnology company focused in the development of  radiopharmaceuticals for targeted diagnosis and therapy of cancer, entered into an agreement to co-develop a novel treatment against neuroendocrine tumors (NETs) using Targeted Alpha Therapy with lead-212 (212Pb).


    In 2016, AREVA Med and Morphotek, a subsidiary of Eisai Inc., entered into a collaborative project to assess the potential of a novel alpha radioimmunotherapy treatment targeting the supporting microenvironment of solid tumors.

    Nordic Nanovector

    In 2016, AREVA Med and Nordic Nanovector, a Norwegian biotech company focusing on the development and commercialization of novel targeted therapeutics in hematology and oncology, announced a collaboration agreement to investigate the potential of a 212Pb-conjugated anti-CD37 antibody for the treatment of leukaemias, orphan diseases with still significant unmet medical need.

    National Cancer Institute (NCI)

    In 2008, AREVA Med and the United States National Cancer  Institute  (NCI)  signed  a  Cooperative  Research and Development Agreement for the design of a new radiopharmaceutical drug using 212Pb.

    University of Cincinnati

    In 2010, AREVA Med and the University of Cincinnati Ohio collaborated on a preclinical study to develop a new treatment to combat prostate cancer.

    French National Institute of Health and Medical Research (Inserm)

    In 2011, AREVA Med signed a cooperative research agreement with the French National Institute of Health and Medical Research (Inserm).

    University of Alabama at Birmingham (UAB)

    In 2012, AREVA Med launched the first Phase 1 clinical trial using 212Pb at the University of Alabama at Birmingham (UAB).  The goal was to study the safety, distribution, pharmacokinetics, immunogenicity, and tumor response of intraperitoneal 212Pb-TCMC-trastuzumab in patients with human epidermal growth factor receptor type 2 (HER-2)-expressing malignancy.  The latest results were published in the Journal of Clinical Oncology.  

    In 2015, AREVA Med and five research partners received support from Bpifrance for the CARAT Project.

    CARAT (Consortium for alpha radiotherapy applications) is led by AREVA Med to develop a French sector for the production of lead-212 and for treatments using this rare metal.

    Coordinated by AREVA Med, CARAT unites EVEON, Triskem International, the Limoges University Hospital, the CRIBL* laboratory at Limoges University, and Subatech.  Classified as a decisive research and development project for competitiveness (PSPC), this project will receive 9.6 million euros in financing over a 3-½ year period under a program steered by the Commissariat Général à l’Investissement (CGI - French General Investment Commission).

    With the implementation of the CARAT project and thanks to our existing production facilities, AREVA Med will have the opportunity to fulfill expected 212Pb clinical development needs.

    *Control of the B Cell Immune Response and Lymphoproliferations

AREVA Med Video

Click here to view the latest AREVA Med Video


For more information about AREVA Med, please contact:
Alison Tise
Tel.: + 1 (301) 841-1673

CEO Cancer Gold Standard

AREVA Med receives CEO Cancer Gold Standard accreditation